192 related articles for article (PubMed ID: 22607870)
21. Frequency and outcomes of provisional glycoprotein IIb/IIIa blockade in patients receiving bivalirudin during percutaneous coronary intervention.
Feldman DN; Wong SC; Bergman G; Minutello RM
J Invasive Cardiol; 2009 Jun; 21(6):258-63. PubMed ID: 19494400
[TBL] [Abstract][Full Text] [Related]
22. Distal myocardial protection with intracoronary beta blocker when added to a Gp IIb/IIIa platelet receptor blocker during percutaneous coronary intervention improves clinical outcome.
Uretsky BF; Birnbaum Y; Osman A; Gupta R; Paniagua O; Chamoun A; Pohwani A; Lui C; Lev E; McGehee T; Kumar D; Akhtar A; Anzuini A; Schwarz ER; Wang FW
Catheter Cardiovasc Interv; 2008 Oct; 72(4):488-97. PubMed ID: 18814223
[TBL] [Abstract][Full Text] [Related]
23. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, eptifibatide and abciximab: outcomes, complications and thrombocytopenia during percutaneous coronary intervention.
Suleiman M; Gruberg L; Hammerman H; Aronson D; Halabi M; Goldberg A; Grenadier E; Boulus M; Markiewicz W; Beyar R
J Invasive Cardiol; 2003 Jun; 15(6):319-23. PubMed ID: 12777670
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of triple antiplatelet therapy with and without concomitant anticoagulation during elective percutaneous coronary intervention (the REMOVE trial).
Valencia R; Price MJ; Sawhney N; Lee SS; Wong GB; Gollapudi RR; Banares M; Schatz RA; Teirstein PS
Am J Cardiol; 2007 Oct; 100(7):1099-102. PubMed ID: 17884370
[TBL] [Abstract][Full Text] [Related]
25. Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) trial.
Leon MB; Nikolsky E; Cutlip DE; Mauri L; Liberman H; Wilson H; Patterson J; Moses J; Kandzari DE;
JACC Cardiovasc Interv; 2010 Oct; 3(10):1043-50. PubMed ID: 20965463
[TBL] [Abstract][Full Text] [Related]
26. Regular Drug-Eluting Stent vs Dedicated Coronary Bifurcation BiOSS Expert Stent: Multicenter Open-Label Randomized Controlled POLBOS I Trial.
Gil RJ; Bil J; Džavík V; Vassilev D; Kern A; Formuszewicz R; Zalewska-Adamiec M; Dobrzycki S
Can J Cardiol; 2015 May; 31(5):671-8. PubMed ID: 25828372
[TBL] [Abstract][Full Text] [Related]
27. Six-month outcomes of percutaneous coronary balloon angioplasty in acute coronary syndromes: Results from the PURSUIT trial.
Labinaz M; Kaul P; Harrington RA; Chang WC; Kleiman NS; Simoons ML; Boersma E; Akkerhuis KM; Califf RM; Armstrong PW;
Can J Cardiol; 2004 Jun; 20(8):773-8. PubMed ID: 15229770
[TBL] [Abstract][Full Text] [Related]
28. Relationship between the intensity of heparin anticoagulation and clinical outcomes in patients receiving glycoprotein IIb/IIIa inhibitors during primary percutaneous coronary intervention in acute myocardial infarction.
Rozenman Y; Mehran R; Witzenbichler B; Dangas G; Desaga M; Kochman J; Nilsen DW; Finkelstein A; Mosseri M; Stone GW
Catheter Cardiovasc Interv; 2013 Jan; 81(1):E9-14. PubMed ID: 22511592
[TBL] [Abstract][Full Text] [Related]
29. Comparison of double kissing crush versus Culotte stenting for unprotected distal left main bifurcation lesions: results from a multicenter, randomized, prospective DKCRUSH-III study.
Chen SL; Xu B; Han YL; Sheiban I; Zhang JJ; Ye F; Kwan TW; Paiboon C; Zhou YJ; Lv SZ; Dangas GD; Xu YW; Wen SY; Hong L; Zhang RY; Wang HC; Jiang TM; Wang Y; Chen F; Yuan ZY; Li WM; Leon MB
J Am Coll Cardiol; 2013 Apr; 61(14):1482-8. PubMed ID: 23490040
[TBL] [Abstract][Full Text] [Related]
30. Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study.
Gurbel PA; Bliden KP; Zaman KA; Yoho JA; Hayes KM; Tantry US
Circulation; 2005 Mar; 111(9):1153-9. PubMed ID: 15738352
[TBL] [Abstract][Full Text] [Related]
31. Randomized Comparisons Between Different Stenting Approaches for Bifurcation Coronary Lesions With or Without Side Branch Stenosis.
Kim YH; Lee JH; Roh JH; Ahn JM; Yoon SH; Park DW; Lee JY; Yun SC; Kang SJ; Lee SW; Lee CW; Seung KB; Shin WY; Lee NH; Lee BK; Lee SG; Nam CW; Yoon J; Yang JY; Hyon MS; Lee K; Jang JS; Kim HS; Park SW; Park SJ
JACC Cardiovasc Interv; 2015 Apr; 8(4):550-60. PubMed ID: 25907082
[TBL] [Abstract][Full Text] [Related]
32. Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial.
Stone GW; Witzenbichler B; Guagliumi G; Peruga JZ; Brodie BR; Dudek D; Kornowski R; Hartmann F; Gersh BJ; Pocock SJ; Dangas G; Wong SC; Fahy M; Parise H; Mehran R;
Lancet; 2011 Jun; 377(9784):2193-204. PubMed ID: 21665265
[TBL] [Abstract][Full Text] [Related]
33. 5-year outcomes following percutaneous coronary intervention with drug-eluting stent implantation versus coronary artery bypass graft for unprotected left main coronary artery lesions the Milan experience.
Chieffo A; Magni V; Latib A; Maisano F; Ielasi A; Montorfano M; Carlino M; Godino C; Ferraro M; Calori G; Alfieri O; Colombo A
JACC Cardiovasc Interv; 2010 Jun; 3(6):595-601. PubMed ID: 20630452
[TBL] [Abstract][Full Text] [Related]
34. Five-year long-term clinical follow-up of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT FIRST trial.
Wiemer M; Serruys PW; Miquel-Hebert K; Neumann FJ; Piek JJ; Grube E; Haase J; Thuesen L; Hamm C
Catheter Cardiovasc Interv; 2010 Jun; 75(7):997-1003. PubMed ID: 20517959
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of a double-coated paclitaxel-eluting coronary stent: the EUCATAX trial.
Rodriguez AE; Vigo CF; Delacasa A; Mieres J; Fernandez-Pereira C; Bernardi V; Bettinoti M; Rodriguez-Granillo AM; Rodriguez-Granillo G; Santaera O; Curotto V; Rubilar B; Tronge J; Palacios IF; Antoniucci D;
Catheter Cardiovasc Interv; 2011 Feb; 77(3):335-42. PubMed ID: 20824769
[TBL] [Abstract][Full Text] [Related]
36. Influence of timing of clopidogrel treatment on the efficacy and safety of bivalirudin in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention: an analysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.
Lincoff AM; Steinhubl SR; Manoukian SV; Chew D; Pollack CV; Feit F; Ware JH; Bertrand ME; Ohman EM; Desmet W; Cox DA; Mehran R; Stone GW;
JACC Cardiovasc Interv; 2008 Dec; 1(6):639-48. PubMed ID: 19463378
[TBL] [Abstract][Full Text] [Related]
37. Eptifibatide is noninferior to abciximab in primary percutaneous coronary intervention: results from the SCAAR (Swedish Coronary Angiography and Angioplasty Registry).
Akerblom A; James SK; Koutouzis M; Lagerqvist B; Stenestrand U; Svennblad B; Oldgren J
J Am Coll Cardiol; 2010 Aug; 56(6):470-5. PubMed ID: 20670756
[TBL] [Abstract][Full Text] [Related]
38. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial.
ESPRIT Investigators. Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy
Lancet; 2000 Dec; 356(9247):2037-44. PubMed ID: 11145489
[TBL] [Abstract][Full Text] [Related]
39. High-dose, single-bolus eptifibatide: a safe and cost-effective alternative to conventional glycoprotein IIb/IIIa inhibitor use for elective coronary interventions.
Fischell TA; Attia T; Rane S; Salman W
J Invasive Cardiol; 2006 Oct; 18(10):487-91. PubMed ID: 17042093
[TBL] [Abstract][Full Text] [Related]
40. Bivalirudin versus heparin plus a glycoprotein IIb/IIIa inhibitor in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention after clopidogrel pretreatment: pooled analysis from the ACUITY and ISAR-REACT 4 trials.
Ndrepepa G; Neumann FJ; Deliargyris EN; Mehran R; Mehilli J; Ferenc M; Schulz S; Schömig A; Kastrati A; Stone GW
Circ Cardiovasc Interv; 2012 Oct; 5(5):705-12. PubMed ID: 23048052
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
